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Abstract: The prevalence of antimicrobial resistance in India is among the highest in the world.
Antimicrobial use in inpatient settings is an important driver of resistance, but is poorly characterized,
particularly in hospitalized children. In this study, conducted as part of the Global Antimicrobial
Resistance, Prescribing, and Efficacy in Neonates and Children (GARPEC) project, we examined
the prevalence of and indications of antimicrobial use, as well as antimicrobial agents used
among hospitalized children by conducting four point prevalence surveys in six hospitals between
February 2016 and February 2017. A total of 681 children were hospitalized in six hospitals
across all survey days, and 419 (61.5%) were prescribed one or more antimicrobials (antibacterials,
antivirals, antifungals). Antibacterial agents accounted for 90.8% (547/602) of the total antimicrobial
prescriptions, of which third-generation cephalosporins (3GCs) accounted for 38.9% (213/547) and
penicillin plus enzyme inhibitor combinations accounted for 14.4% (79/547). Lower respiratory tract
infection (LRTI) was the most common indication for prescribing antimicrobials (149 prescriptions;
24.8%). Although national guidelines recommend the use of penicillin and combinations as first-line
agents for LRTI, 3GCs were the most commonly prescribed antibacterial agents (55/149 LRTI
prescriptions; 36.9%). In conclusion, 61.5% of hospitalized children were on at least one antimicrobial
agent, with excessive use of 3GCs. Hence there is an opportunity to limit their inappropriate use.
Keywords: point prevalence survey; antimicrobial use; children; hospital; India
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1. Introduction
Antimicrobial resistance is rising across the globe, with prevalence in India reported as being
among the highest [1,2]. A recent study reported that resistance to last-resort antimicrobials increased
between 2008 and 2014 [3]. In 2014, 57% of Klebsiella pneumoniae and 10% of Escherichia coli blood culture
isolates were observed to be carbapenem resistant. The high proportion of bacterial infections due to
extended spectrum beta-lactamase (ESBL)-producing organisms is one reason for the high consumption
of carbapenems in India. Among 51 countries for which antimicrobial resistance surveillance data
were available in 2014, India had the highest proportion of third-generation cephalosporin-resistant
E. coli (83%), an indirect marker for ESBL production [4].
Antimicrobial selection pressure is a primary driver of resistance development [5], and there is an
urgent need to reduce antimicrobial overuse and misuse. Surveillance of antimicrobial use in hospitals
can provide an insight into patterns of antimicrobial use, help highlight differences in prescribing
practices among hospitals, and identify opportunities for improvement. Information on antimicrobial
use from point prevalence surveys (PPSs) could be used to design, implement, and assess the effects of
antimicrobial policies [6]. To date, only one multicenter (>2 hospitals) study describing antimicrobial
use among hospitalized children has been published in India [7]. However, this study did not collect
information on the total number of children admitted to various wards and thus could not estimate the
rate of antimicrobial use per patient. In this study, we examined the prevalence of and indications of
antimicrobial use, as well as the antimicrobial agents used among hospitalized children, by conducting
four PPSs in six hospitals in India.
2. Methods
As part of the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and
Children (GARPEC) study, the participating hospitals were asked to conduct a one-day cross-sectional
hospital based PPSs in all pediatric and neonatal wards four times between 1 February 2016 and
28 February 2017. The Antibiotic Resistance and Prescribing in European Children (ARPEC) project
PPS methodology was utilized for this study [8]. Four single-day PPSs on antimicrobial use were
conducted between 1 February 2016 and 28 February 2017. The first PPS was conducted between
1 February and 31 March 2016; the second between 1 May and 30 June 2016; the third between
1 September and 31 October 2016; and the fourth between 1 December 2016 and 28 February 2017.
Four PPSs were conducted to increase the precision of measurement of antimicrobial use and to
examine the variation of antimicrobial use at different time points.
Each hospital needed to register providing the name, geographic location and type of hospital
(primary, secondary and tertiary level and teaching vs. nonteaching hospital). Hospitals were asked
to conduct the survey only on a weekday during the designated months of each round of PPS.
All neonates and pediatric hospitalized patients younger than 18 years of age, present in the ward at
8:00 a.m., were included in the survey. Detailed data were recorded only for patients with an active
antimicrobial prescription at 8 am on the day of survey.
At the time of initiation of the study on 1 February 2016, five hospitals were enrolled into the study.
Three additional hospitals were enrolled by 1 May 2016 and did not participate in the first round of
PPS. Among the eight hospitals, two were rural general trust hospitals, three were stand-alone private
children’s hospitals, two were private tertiary care hospitals and one was a private mother and child
care center with inborn neonatal services. One tertiary care hospital had teaching services in pediatrics
and neonatal departments. Two stand-alone pediatric hospitals and the mother and child care center
had teaching services in neonatal departments. PPSs were conducted in the neonatal intensive care
units and neonatal wards of all eight hospitals and the pediatric units (including pediatric intensive
care units) of only six hospitals (one hospital had only neonatal services and the other hospital restricted
the study to neonatal units). In this study, we examined the antimicrobial use patterns among the
pediatric units of six hospitals. Antimicrobial use in neonatal intensive care units and general neonatal
wards were not examined in this study.
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Hospital, department, and de-identified patient data were collected using a standardized
web-based electronic data entry form on the Research Electronic Data Capture (REDCap)® developed
for the GARPEC project. For children receiving antimicrobials (antibiotics, antifungal and antivirals,
antiparasital agents), data were collected on patient sex, age, weight, ventilation status, comorbid
conditions, number of antimicrobials, antimicrobial name, dose per administration, dose units, number
of doses each day, route of administration, reason for treatment, treatment indication (community
versus healthcare associated) or prophylaxis, and whether treatment was empirical or targeted.
We included all diagnoses for which antimicrobials were prescribed even if there was more than
one diagnosis. Ethics approval was received for all participating hospitals from their respective
institutional human research ethics committees.
Categorical variables were expressed as percentages, and the chi-squared test or Fisher’s exact test
was used, as appropriate, for comparisons. Statistical significance was defined as p < 0.05. The statistical
analyses were performed using STATA 12.1 (StataCorp, College Station, TX, USA).
3. Results
At the six participating hospitals, the total number of beds for all four survey days ranged from
24 to 517, and the bed occupancy ranged from 15.1% to 79.8% (Table 1).
Table 1. Characteristics, bed occupancy, and antimicrobial prescription in six hospitals in India in 2016.
Hospital
ID
Hospital
Characteristics
Total
Beds
Total
Patients
(N)
Bed
Occupancy
(%)
Intensive
Care Beds
(Yes/No)
Patients on
Antimicrobials
(N)
Patients on
Antimicrobials
(%)
A * Rural general hospital 149 92 61.7 Y 51 55.4
B Stand-alone pediatric 112 79 70.5 Y 57 72.2
C * Rural general hospital 119 95 79.8 N 76 80.0
D # Tertiary care hospital 517 385 74.5 Y 212 55.1
E * Tertiary care hospital 24 14 58.3 Y 13 92.9
F ** Stand-alone pediatric 106 16 15.1 Y 10 62.5
All 1027 681 66.3 419 61.5
Note: Hospitals A, B, and F have only medical intensive care units; Hospitals D and E have surgical intensive care
beds available in addition to medical. * Did not participate in the first point prevalence survey; ** Did not participate
in the second point prevalence survey; # Has teaching services in pediatric departments.
A total of 681 children were hospitalized in six hospitals across all survey days, and 419 (61.5%)
were prescribed one or more antimicrobials. The percentage of children on antimicrobials in the six
hospitals ranged from 55.1% to 92.9% (Table 1). One antimicrobial was prescribed to 291 patients,
two antimicrobials were prescribed to 85 patients, and three or more were prescribed to 43 patients.
The percentages of patients on antimicrobials for the four PPSs were 61.3% (73/119), 59.4% (104/175),
63.6% (133/209), and 61.2% (109/178), respectively.
Of the 419 children receiving antimicrobials, 147 (35.1%) were less than one year old, and 248
(59.2%) were male (Table 2).
Only one hospital (Hospital D) had two dedicated surgical wards. The remaining five hospitals
had general pediatric wards, where both medical and surgical patients were admitted. Pediatric
intensive care units were present in five hospitals, of which two had dedicated surgical intensive
care units. General pediatric wards accounted for 78.5% (329) of children on antimicrobials, and
intensive care units accounted for the remaining 21.5% (90) (Table 2). The percentage of patients
on antimicrobials was significantly higher in intensive care units than in general pediatric wards
(73.4% vs. 59.0%; p = 0.003). The average number of antimicrobials per patient was higher in intensive
care units (mean 1.5; range 1–4) than in general pediatric wards (mean 1.4; range 1–5). In 419 patients
with an antimicrobial prescription, 343 (81.8%) were prescribed for treatment of active infection and
76 (18.2%) for prophylaxis. Lower respiratory tract infections (LRTIs) (117, 27.9%), sepsis (66, 15.7%),
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and prophylaxis for surgical disease (49, 11.7%) were the three most common reasons for prescribing
antimicrobials (Table 2).
Table 2. Percentages of hospitalized children on antimicrobials in six hospitals in India in 2016.
Characteristic Number ofChildren (N = 419)
Percentage
of Children
Number of
Prescriptions (N = 602)
Percentage of
Prescriptions
Underlying comorbid conditions 256 61.1 359 59.6
No underlying disease 163 38.9 243 40.4
Age category
Age < 1 147 35.1 197 32.7
Age 1–6 173 41.2 255 43.2
Age 7–12 79 18.8 118 19.6
Age > 12 20 4.8 32 5.5
Gender
Male 248 59.2 354 58.6
Ward activity
Intensive care units 90 21.5 138 22.9
General wards 329 78.5 464 77.1
Diagnosis *
Lower respiratory tract infection (LRTI) 117 27.9 149 24.8
Sepsis 67 15.9 90 15.0
Prophylaxis for surgical disease 50 11.9 77 12.8
Treatment for surgical disease 34 8.1 64 10.6
Prophylaxis for medical problems 29 6.9 41 6.6
Other 80 19.0 116 19.3
Upper respiratory infections (URTI) 17 4.1 23 3.8
Urinary tract infections (UTI) 18 4.3 22 3.7
GI tract infections 19 4.5 21 3.5
Indication *
Community-acquired infection (CAI) 233 55.6 313 52.0
Healthcare-associated infection (HAI) 40 9.5 55 9.1
Unknown 79 18.9 116 19.3
Prophylaxis (medical and surgical) 79 18.9 118 19.6
* Total can be more than 100% as one patient can have more than one diagnosis.
Of the 602 total antimicrobial prescriptions, 313 (52%) were for community-acquired infections
(CAIs), 55 (9.1%) were for healthcare associated infections (HAI), and 116 (19.3%) were for unknown
indications (CAI or HAI) (Table 2). Of the 602 prescriptions, 118 (19.6%) were for medical and surgical
prophylaxis. Among the 313 prescriptions for CAIs, 283 (90.4%) were empiric, whereas 35 (63.6%) of
55 prescriptions for HAIs were empiric. Of the 313 antimicrobial prescriptions for CAIs, the majority
were prescribed for LRTI (133 prescriptions; 42.5%) and sepsis (54 prescriptions; 17.3%).
Antibacterial agents accounted for 90.8% (547 of 602) of total antimicrobial prescriptions.
Of the 547 antibacterial prescriptions, the three most common classes of antibiotics prescribed were
third-generation cephalosporins (213 of 547 prescriptions; 38.9%), penicillin plus enzyme inhibitor
combinations (78 of 547 prescriptions; 14.3%), and aminoglycosides (57 of 547 prescriptions; 10.4%)
(Table 3).
The top three classes of antibacterial agents and their order were similar in each of the four PPSs.
Carbapenems and fluoroquinolones accounted for less than 5% each of total antibacterial prescriptions,
respectively (Table 3).
Of the prescriptions for carbapenems, 55.5% (15/27) were prescribed in intensive care units. The
top three reasons for prescribing carbapenems were sepsis (4 HAI and 1 CAI), LRTI (3 CAI and 1 HAI),
and central nervous system infections (2 CAI and 1 unknown). Overall, the three most commonly
prescribed antimicrobials were ceftriaxone (111 of 602 prescriptions; 18.4%), amoxicillin-clavulanic
acid (69 of 602 prescriptions; 11.5%), and cefotaxime (58 of 602 prescriptions; 9.6%) (Figure 1).
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Table 3. Antimicrobial prescriptions for all indications among hospitalized children in six hospitals in
India in 2016.
All Hospital A Hospital B Hospital C Hospital D Hospital E Hospital F
Children on ≥1 antimicrobials 432 93 108 95 388 14 14
Total number of prescriptions 602 77 90 91 306 26 12
Third-generation cephalosporins 213 25 44 16 108 12 8
Penicillin + enzyme inhibitors 78 13 3 44 16 1 1
Others * 73 13 16 19 22 3 0
Aminoglycosides 57 11 4 1 31 10 0
Penicillins 35 4 1 0 29 0 1
Metronidazole 33 0 2 2 29 0 0
Carbapenems 27 2 3 1 21 0 0
Fluoroquinolones 20 1 6 0 13 0 0
First/second-generation cephalosporins 18 0 0 0 18 0 0
Macrolides 16 1 6 2 6 0 1
Glycopeptides 14 3 3 0 8 0 0
Trimethoprim/sulfa 12 3 1 4 4 0 0
Tetracycline 6 1 1 2 1 0 1
* Others included chloramphenicol, clindamycin, linezolid, doxycycline, tigecycline, colistin, and antituberculosis,
antifungal, antiviral, and antimalarial agents.
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Figure 1. Prescribed antimicrobials among hospitalized children, ranked by overall drug utilization
75% (DU75%).
The five diagnoses associated with the highest rates of antimicrobial prescribing were LRTI
(149 of 602 prescriptions; 24.8%), sepsis (90 of 602 prescriptions; 15%), prophylaxis for surgical disease
(77 of 602 prescriptions; 12.8%), treatment of surgical disease (64 of 602 prescriptions; 10.6%), and
prophylaxis for medical problems (41 of 602 prescriptions; 6.8%) (Table 2). The two most commonly
prescribed antibacterial classes for LRTI were third-generation cephalosporins (55 of 149 prescriptions;
36.9%) and penicillin plus enzyme inhibitor combinations (46 of 149 prescriptions; 30.9%). For LRTI,
third-generation cephalosporins were mainly used as monotherapy (38/55) and in combination in
17 other cases, mostly with macrolides (5/17). The two most common antibacterial agents prescribed
for sepsis were the third-generation cephalosporins (40 of 90 prescriptions; 44.4%) and amikacin
(11 of 90 prescriptions; 12.2%). For sepsis cases, third-generation cephalosporins were mainly used as
monotherapy (26/40) and in combination in 14 other cases, mostly with amikacin (8/14).
In cases of prophylaxis for surgical disease, the two most commonly prescribed antibacterial
classes were third-generation cephalosporins (29 of 64 prescriptions; 37.7%) and aminoglycosides (16 of
64 prescriptions; 25%). Third-generation cephalosporins were used as monotherapy in 9 cases and in
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combination in 20 other cases, mostly with aminoglycosides (8/20) and with both aminoglycosides and
metronidazole (4/20). Third-generation cephalosporins were the most commonly used antibacterial
agents (14/41) used for medical prophylaxis. They were used as monotherapy in six patients in
combination mainly with aminoglycosides in eight patients (4/8).
4. Discussion
To the best of our knowledge, this is the first published multicenter study to estimate the
prevalence of antimicrobial use among hospitalized children in India. The percentage of hospitalized
children who received at least one antimicrobial agent was 61.5% in this study. In the global Antibiotic
Resistance and Prescribing in European Children (ARPEC) PPS study conducted in 2012, involving
226 hospitals from 41 countries, the overall percentage of hospitalized children on antimicrobials
was 42.5%, which was much lower than the 61.5% in our study [8]. The percentage of patients on
antimicrobials in our study was higher than reported in Turkey (54.6%) [9], Italy (47%) [10], Australia
(46%) [11], the United Kingdom (40.9%) [12], Latvia (39%) [13], and the United States (33%) [14].
However, it was lower than in Iran (66.6%) [15] and China (78.2%) [16]. Consistent with previous
studies, we observed that the majority of the antimicrobial usage was for therapeutic purposes rather
than prophylaxis [8,10–12,15].
LRTI was the most common indication for prescribing antimicrobials, a finding consistent with
PPSs among hospitalized children in several other countries [10–13]. Third-generation cephalosporins
were the most commonly prescribed antibiotics for LRTI in this study. Similar findings were reported
by another Indian study, which reviewed antibiotic prescription practices among hospitalized children
in two private hospitals in central India [17]. However, the Indian National Center for Disease Control
and Prevention (NCDC) guidelines [18] and the INDIACLEN task force guidelines for pneumonia [19]
recommend ampicillin or ampicillin plus gentamicin or amoxicillin-clavulanic acid as first-line therapy
for LRTI among hospitalized children older than two months. Third-generation cephalosporins are
recommended in hospitalized children only when they deteriorate on first-line agents.
Consistent with our findings, third-generation cephalosporins were the most commonly
prescribed antimicrobials in Eastern Europe (35.7%) and Asia (28.6%) in the global ARPEC study [8],
as well as in Turkey (18.4%) [9], Italy (20%) [10], Latvia (28%) [13], and Iran (43.5%) [15]. However,
in Australia and the United Kingdom, penicillin plus enzyme inhibitor combinations were the most
commonly prescribed antimicrobials [11,12]. Carbapenem prescription in this study was lower than in
Turkey (12.7%) [9], Italy (6%) [10], and Iran (5.2%) [15], but higher than in Australia (3.2%) [11] and
Latvia (0.5%) [13]. However, it is possible that carbapenem consumption has been underestimated
because of the lack of representation of tertiary care centers with large numbers of intensive care unit
beds in this study.
The study has several strengths. First, the repeated PPSs in the six hospitals increased the
robustness of our estimates of antimicrobial prescription among hospitalized children. Second,
the six participating hospitals represented diverse settings that are commonly seen in India.
Two hospitals were small stand-alone children hospitals in urban areas, two were part of a rural
general hospital, and two were part of large tertiary care referral centers. Thus we were able to
capture antimicrobial prescribing practices in different hospital settings. Third, we examined for the
variation of antimicrobial use at different times of the year. Interestingly, the percentages of children
on antimicrobials and the antimicrobial prescription patterns in each of the four PPSs were similar
when compared with combined data from all four PPSs. We did not observe any temporal variation in
antimicrobial prescribing.
The study also has several limitations, however. First, we did not collect data on the duration of
therapy, nor the microbiology and antimicrobial susceptibility results, which could help indicate the
appropriateness of antimicrobial prescribing; Second, although we included hospitals with different
characteristics, we did not include large academic centers and hospitals from all regions of India.
This would require a much larger study. Thus, our results may not be generalizable to all healthcare
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settings and geographic regions of the country. Similarly, as all hospitals included in the study were
from the private sector, the results may not be generalizable to public sector hospitals. The choice of
antibiotics may differ in public hospitals as the national and state drug policies often define the types of
antibiotics procured and prescribed in the public sector hospitals. The public sector hospitals are also
obliged to follow national prescribing guidelines; Third, five out of six hospitals did not have dedicated
surgical wards or other specialized units such as hematology-oncology or cardiology, which limited
our ability to study variation of antimicrobial use across different hospital units; Fourth, with Hospital
D having most number of beds and patients in the study, the results could have been biased affecting
the representativeness of the data; Fifth, the date of the survey was chosen as per the convenience of
the site principal investigator within the specified months. However, we have not taken additional
steps to minimize the Hawthorne effect. As the physicians knew that their antimicrobial prescriptions
were being studied, the results might have been affected. Sixth, 79 (19%) of the prescriptions had
unknown indications (where it was not known whether the infection was community acquired or
healthcare associated), however, we have not taken additional efforts to identify the indications.
Our study identified an opportunity to improve antimicrobial use for LRTI among hospitalized
children. The current guidelines recommend the use of third-generation cephalosporins only when
there is deterioration in the effectiveness of first-line agents. However, in our study, the majority of
hospitalized children with LRTI were on third-generation cephalosporins. A recent study assessing
the antibiotic susceptibility of the major bacterial pathogens isolated from community-acquired
pneumonia among both adults and children in India indicated high susceptibility to first-line agents
(ampicillin and amoxicillin-clavulanic acid) [20]. In this study, 91.8% of Streptococcus pneumoniae
isolates were susceptible to amoxicillin. Similarly, 91.1% of Haemophilus influenzae isolates were
susceptible to ampicillin, and 97% of the H. influenzae isolates were susceptible to amoxicillin-clavulanic
acid [20]. This study reinforces that third-generation cephalosporins can be avoided as first-line
therapy for LRTI. We also observed that third-generation cephalosporins were the most commonly
used antibiotics for surgical prophylaxis. However, the published international guidelines recommend
use of first- and second-generation cephalosporins for surgical prophylaxis instead of third-generation
cephalosporins [21].
Reviewing national antimicrobial resistance surveillance data obtained both from adults and
children, in 2014, 83% of the E. coli isolates were resistant to third-generation cephalosporins in India,
which was much higher than in Australia (9%), the United Kingdom (11%), Argentina (14%), the United
States (16%), South Africa (19%), and China (62%) [22,23]. Use of third-generation cephalosporins is
associated with increased the risk of colonization with ESBL-producing bacteria [24]. Third-generation
cephalosporin exposure in children could lead to colonization at a very young age, which could
facilitate the spread of ESBL-producing bacteria to other family members, leading to a further increase
in ESBL Enterobacteriaceae infections and subsequently the consumption of carbapenems in India.
Our findings indicate the need for increased compliance with NCDC and INDIACLEN treatment
guidelines for the management of LRTI in children.
In conclusion, 61.5% of the hospitalized children were on at least one antimicrobial agent.
We observed an excessive use of third-generation cephalosporins for LRTI. There is an opportunity to
limit the use of third-generation cephalosporins by following the recommended national treatment
guidelines for management of LRTI.
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